Economic Survey 2025-26 Highlights India’s Shift Toward High-Value Pharma and Innovation

I have enough facts. Writing the note.

Economic Survey 2025-26 — India's Shift Toward High-Value Pharma & Innovation

1. At a Glance

• Economic Survey 2025-26 (tabled Jan 2026) flags Indian pharma's transition from a volume-driven generics powerhouse to a value-driven complex-generics, biosimilars and innovation ecosystem [S1][S2].
• Medical devices sector emerging as a high-tech global manufacturing hub, exporting to 187 countries in FY25 [S1].
• Relevant for GS-III (Indian economy, manufacturing, S&T) and government schemes (PLI, Bulk Drug Parks, Medical Device Parks, PMBJP).

2. Why in the News

• Department of Pharmaceuticals press release (30 Jan 2026) on chapter of Economic Survey 2025-26 dedicated to pharma & medical devices [S1].
• Coincides with India's improved Global Innovation Index rank: 38th in 2025 (from 66th in 2019) [S3].

3. Background & Evolution

• India historically the "pharmacy of the world" — 3rd globally by volume, supplying ~20% of global generics.
• PLI for Bulk Drugs (KSMs/APIs) launched 2020 to cut China dependence; PLI for Medical Devices launched 2020; PLI 2.0 for Pharma notified 2021 [S2].
• Bulk Drug Parks scheme (₹3,000 cr) and Medical Device Parks scheme (₹400 cr) approved 2020 for shared infrastructure.
• Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) launched 2008, relaunched 2015 [S4].

4. Core Static Facts

• Nodal ministry: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S1].
• Pharma turnover FY25: ~₹4.72 lakh crore; export CAGR (FY15-FY25): ~7% [S2].
• Global rank: 3rd by volume, 11th by value in pharma exports [S2].
• Pharma exports reach 191 countries in FY25; ~50% to highly regulated markets (US, EU) [S2].
• Medical device exports: USD 2.5 bn (FY21) → USD 4.1 bn (FY25); exports to 187 countries [S1][S2].
• High-end devices manufactured: MRI, CT scanners, linear accelerators, cardiac stents, ventilators [S1].
• PLI (overall): 14 sectors, outlay ₹1.97 lakh crore; investment realised >₹2.0 lakh cr; production/sales >₹18.70 lakh cr; employment >12.6 lakh; ₹23,946 cr disbursed (till Sep 2025) [S2].
• PMBJP: 18,646 Jan Aushadhi Kendras (Mar 2026); FY25 sales ₹2,022.47 cr; citizen savings ≈ ₹8,000 cr [S4].
• Industry size: >3,000 companies, 10,500 manufacturing units [S2].

5. Multi-Dimensional Analysis

Economic - Shift to complex generics/biosimilars raises unit value realisation, narrows trade deficit in APIs [S1]. - PLI-led capex realisation of ₹2 lakh cr signals private investment crowding-in [S2].

Scientific / Technological - Domestic capacity in linear accelerators, MRI/CT scanners marks move up the medtech value chain [S1]. - India's GII rank 38 (2025), up from 66 in 2019, supports innovation thrust [S3].

Strategic / Geopolitical - API self-reliance reduces dependence on Chinese KSMs — supply-chain security post-COVID [S2]. - Exports to 187/191 countries project India as alternate global supplier under "China+1".

Social - Jan Aushadhi Kendras lower out-of-pocket health expenditure; ₹8,000 cr savings in FY25 [S4]. - Affordable biosimilars expand access to oncology/biologics.

Administrative - Multiple PLI tracks (Bulk Drugs, Medical Devices, Pharma 2.0) administered by DoP; parks scheme co-implemented with states.

6. Recent Developments (last 12-18 months)

• 30 Jan 2026 — Economic Survey 2025-26 pharma/medtech chapter released [S1].
• Jan 2026 — Survey notes GII rank 38 for India in 2025 [S3].
• Till Sep 2025 — PLI cumulative disbursal ₹23,946 cr across 12 sectors; 806 applications approved [S2].
• FY25 — Pharma exports to 191 countries; medical devices to 187 countries [S1][S2].
• Mar 2026 — Jan Aushadhi Kendra count reaches 18,646 [S4].

7. Prelims Hooks

• Pharma sector regulator nodal body: Department of Pharmaceuticals, Min. of Chemicals & Fertilizers [S1].
• India's rank in global pharma exports: 3rd by volume, 11th by value [S2].
• PLI total outlay across 14 sectors: ₹1.97 lakh crore [S2].
• Bulk Drug Parks scheme outlay: ₹3,000 crore (4 parks).
• Medical Device Parks scheme outlay: ₹400 crore.
• Medical device exports FY25: USD 4.1 billion to 187 countries [S1][S2].
• Pharma exports FY25 reach: 191 countries; ~50% to US/EU [S2].
• India's GII rank 2025: 38 (up from 66 in 2019) [S3].
• Jan Aushadhi Kendras (Mar 2026): 18,646; FY25 sales ₹2,022.47 cr [S4].
• PMBJP launched: 2008; nodal: PMBI under DoP [S4].
• Pharma turnover FY25: ~₹4.72 lakh crore [S2].
• Survey identifies thrust areas: complex generics, biosimilars, innovation [S1].

8. Mains Relevance

• GS-III: Indian Economy — "Effects of liberalisation on the economy, changes in industrial policy"; "Science & Technology — developments and their applications".
• Possible stems: 1. "Discuss how the PLI scheme is enabling India's pharmaceutical sector to move from a volume-driven to a value-driven model." (15 marks) 2. "Examine the strategic significance of India's emerging medical devices manufacturing ecosystem in the context of global supply-chain realignment." (10 marks) 3. "Affordability and innovation are competing goals in Indian pharma policy. Critically analyse with reference to PMBJP and biosimilars." (15 marks)

9. Related Topics to Study Next

• PLI Scheme (14 sectors) — anchor instrument behind the shift.
• National Pharmaceutical Pricing Authority (NPPA) — price regulation interface.
• Patent Act 1970 / Section 3(d) / Compulsory Licensing — IPR backbone of generics.
• Global Innovation Index (WIPO) — proxy for innovation pivot.
• Ayushman Bharat PM-JAY — demand-side companion to affordable medicines.
• National Medical Devices Policy 2023 — sectoral roadmap.
• API self-reliance & China+1 strategy — supply-chain angle.
• Biosimilars regulation (CDSCO + DBT guidelines) — science/regulation overlap.

10. Common Errors / Trap Areas

• Nodal ministry is Min. of Chemicals & Fertilizers (Dept of Pharmaceuticals) — not Min. of Health.
• India is 3rd by volume, 11th by value — aspirants often invert these.
• Bulk Drug Parks scheme (₹3,000 cr) ≠ Medical Device Parks scheme (₹400 cr).
• PLI total outlay is ₹1.97 lakh cr across 14 sectors, not per sector.
• PMBJP implementing agency is PMBI (Pharmaceuticals & Medical Devices Bureau of India), not CDSCO.

11. Sources

• [S1] Economic Survey 2025-26 Highlights India's Shift Toward High-Value Pharma and Innovation — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221080&reg=3&lang=2 — (tier 1)
• [S2] India's Pharmaceuticals in Global Healthcare (PIB feature, 2026) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2243248 — (tier 1)
• [S3] India's Innovation Performance Strengthens; GII Rank 38 in 2025 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2219992&reg=3&lang=2 — (tier 1)
• [S4] Jan Aushadhi Kendras — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2203000&reg=3&lang=1 — (tier 1)